Mylan, Amgen score unanimous AdComm backing for Roche copycats; Alder raises $161M
→ Mylan and Amgen breezed through their advisory committee reviews on Thursday without any unexpected kickbacks for their two new knockoffs of a pair of Roche megablockbusters. Both won nods in unanimous votes, which is what you’d expect for drugs given a clean assessment by FDA insiders. Mylan was up with MYL-1401O, a biosimilar of Herceptin. Amgen, meanwhile, won applause for its copycat of Avastin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
